Explore more
Merck, vaccine and Robert F. Kennedy Jr.
Digest more
Top News
Overview
Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat.
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as competition intensifies in the oncology space.
Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at seeking approval.
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme Therapeutics.
InvestorsHub on MSN1d
Merck Launches Final-Stage Trial of Dengue Vaccine for ChildrenMerck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric population, the company announced on Thursday. The trial aims to enroll around 12,000 participants aged 2 to 17,
Feedback